Cancer causes fluid buildup because tumors disrupt the body’s normal fluid balance in several ways at once: they make blood vessel walls leaky, they block lymphatic drainage channels, and they deplete the proteins that keep fluid inside blood vessels where it belongs. The specific location of the buildup, whether around the lungs, in the abdomen, near the heart, or even inside the skull, depends on where the cancer sits and which of these mechanisms is dominant. The result is the same in each case: fluid escapes into spaces where it does not belong, accumulates faster than the body can reabsorb it, and begins to cause symptoms.
How Tumors Make Blood Vessels Leak
The most fundamental reason cancer produces fluid buildup is that tumors alter the blood vessels around them. To grow, a tumor needs its own blood supply, so it sends chemical signals that trigger new blood vessel formation. But the vessels that sprout in response to these signals are structurally abnormal. They are irregularly shaped, poorly supported by surrounding tissue, and full of gaps between the cells lining their walls. Fluid, along with dissolved proteins, seeps through those gaps into the surrounding tissue. This leakiness is not a side effect of the cancer; it is built into how tumors sustain themselves.
One of the key signaling molecules tumors use is vascular endothelial growth factor, commonly called VEGF. Beyond stimulating new vessel growth, VEGF directly increases the permeability of existing blood vessels. The higher the local concentration of VEGF, the more fluid escapes. Inflammatory molecules produced by the tumor and by the immune system’s response to it further loosen the junctions between cells in vessel walls.
In the brain, this process takes a specific and particularly dangerous form. Normally, the blood vessels in the brain have an extremely tight seal known as the blood-brain barrier. Brain tumors disrupt that seal. Plasma leaks across the vessel wall into brain tissue, causing swelling around the tumor that can raise pressure inside the skull and worsen neurological symptoms far out of proportion to the tumor’s actual size.1PubMed. Critical Care Management of Cerebral Edema in Brain Tumors
Falling Protein Levels Make Fluid Harder to Hold
A second mechanism works alongside leaky vessels. Albumin, the most abundant protein in your blood, acts like a sponge that holds water inside blood vessels through osmotic pressure. When albumin levels drop, fluid drifts outward into tissues and body cavities more easily. Cancer patients often develop low albumin for several reinforcing reasons: the tumor itself consumes resources, appetite and food intake decline, protein leaks out through the very effusions being drained, and infections accelerate protein breakdown.2JAMA. Management of Fluid Retention in Patients With Advanced Cancer
This creates a vicious cycle. Fluid accumulates, gets drained, and with it goes more protein. Albumin levels fall further, making the next round of accumulation happen faster. Clinicians managing cancer patients with recurrent fluid collections often watch albumin trends closely for exactly this reason, because the protein loss itself becomes a driver of the problem even when the underlying tumor is stable.
When Lymphatic Channels Get Blocked
Your lymphatic system is a network of thin vessels that collects fluid from tissues and returns it to the bloodstream. It acts like a drainage system for the fluid that naturally seeps out of blood capillaries during normal circulation. When cancer disrupts that drainage, the fluid has nowhere to go.
Disruption happens in several ways. Tumors can physically compress or invade lymphatic vessels, blocking flow directly. Surgical removal of lymph nodes, a common step in cancer treatment, eliminates relay stations in the drainage network. Radiation therapy can scar and destroy lymphatic channels in the treated area.3PubMed Central. Cancer-related lymphedema The swelling that results, called lymphedema, differs from fluid accumulation in body cavities. It typically appears in an arm or leg, and the trapped fluid is rich in protein, which makes the tissues feel firm and heavy rather than squishy.
Lymphedema is especially well known after breast cancer treatment, where lymph nodes under the arm are frequently removed or irradiated. But it can follow treatment for any cancer involving lymph node dissection, including melanoma, gynecologic cancers, and cancers of the head and neck. Unlike pleural effusions or ascites, lymphedema tends to be a chronic, long-term problem that persists even after the cancer itself has been treated.
Fluid Around the Lungs
One of the most common forms of cancer-related fluid buildup is malignant pleural effusion, where fluid collects in the thin space between the lung and the chest wall. Lung cancer is the most frequent cause, but breast cancer, lymphoma, and ovarian cancer can all seed that space with malignant cells. Once cancer cells colonize the pleural lining, they trigger inflammation and make the lining’s blood vessels more permeable, pouring fluid into a space that normally holds only a thin film of lubricant.
The symptoms are hard to miss once enough fluid accumulates. Breathlessness comes first, often progressing quickly. Patients describe feeling unable to take a full breath, especially when lying flat. Chest pressure, a dry cough, and reduced exercise tolerance follow. In some cases, the effusion is the first sign that cancer has spread, showing up on imaging before anyone suspected metastatic disease.
Diagnosing the cause usually requires removing a sample of the fluid with a needle and examining it under a microscope. A retrospective study of patients with malignant pleural effusions found that roughly three out of four had cancer cells identified in the fluid on the first attempt at sampling.4PubMed Central. Evaluation of pleural fluid cytology for the diagnosis of malignant pleural effusion: a retrospective cohort study When the initial fluid sample comes back negative but suspicion remains high, a tissue biopsy of the pleural lining often follows.
Fluid in the Abdomen
Malignant ascites, the accumulation of fluid in the abdominal cavity, is one of the more distressing complications of advanced cancer. It develops most often with ovarian, gastric, colon, and pancreatic cancers. In ovarian cancer, ascites is so common it is considered a hallmark of the disease, and the fluid itself plays an active role in spreading tumor cells across the abdominal lining and contributing to treatment resistance.5PubMed Central. The untapped potential of ascites in ovarian cancer research and treatment
The mechanisms overlap with those driving pleural effusions: tumor deposits on the peritoneal lining make local blood vessels leaky, lymphatic drainage from the abdomen gets overwhelmed or blocked, and low albumin levels reduce the blood’s ability to hold onto fluid. But in the abdomen there is an additional factor. The peritoneal surface area is enormous, and once studded with tumor implants, it can produce fluid at a rate the body simply cannot reabsorb.
Patients with malignant ascites notice a progressive increase in abdominal girth, often accompanied by early satiety, nausea, and difficulty breathing as the swollen abdomen pushes up against the diaphragm. Unfortunately, the development of malignant ascites usually signals advanced disease. Average survival from the time of diagnosis is around 20 weeks, though this varies significantly by cancer type and available treatment options.6PubMed Central. Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures
Fluid Around the Heart
A less common but potentially life-threatening location for cancer-related fluid is the pericardial space, the sac that surrounds the heart. Lung cancer is the most frequent culprit, though breast cancer, lymphoma, and leukemia can also cause pericardial effusions. When fluid builds up slowly, the pericardium stretches to accommodate it, and symptoms may be mild at first: vague chest discomfort, shortness of breath, a feeling of fullness. But if fluid accumulates rapidly, or if the volume exceeds what the sac can stretch to hold, it compresses the heart and prevents the chambers from filling properly. This is cardiac tamponade, a medical emergency that requires immediate drainage.7Acta Medica International. Carcinoma Lung Presenting with Cardiac Tamponade due to Malignant Pericardial Effusion: A Case Report
The underlying mechanism is the same pattern seen elsewhere: tumor cells irritate the pericardial lining, increase vessel permeability, and block lymphatic outflow from the sac. What makes pericardial effusion uniquely dangerous is the heart’s sensitivity to even modest external pressure. A relatively small volume of fluid can produce hemodynamic collapse if it accumulates quickly, whereas the pleural and peritoneal spaces can absorb liters before reaching a crisis point.
How Fluid Buildup Is Managed
The first-line response to symptomatic fluid accumulation in cancer is usually drainage. For pleural effusions, this means thoracentesis, where a needle or catheter is inserted between the ribs to draw off the fluid. For ascites, the equivalent procedure is paracentesis. Both provide rapid symptom relief, sometimes dramatically so. A patient who could barely walk across a room may feel markedly better within hours of having a liter of fluid removed.
The problem is recurrence. Malignant effusions tend to come back, often within weeks. Repeated needle procedures carry their own risks and are burdensome for patients, so clinicians look for more durable solutions when the fluid keeps returning.
For pleural effusions, one option is pleurodesis. This involves instilling a chemical irritant, most commonly sterile talc, into the pleural space through a chest tube. The resulting inflammation causes the lung surface to adhere to the chest wall, eliminating the space where fluid was pooling.8PubMed Central. Effectiveness and Safety of Talc Slurry Pleurodesis in the Treatment of Patients with Malignant Pleural Effusion and Low Karnofsky Performance Status Scores It works best when the lung can fully expand to meet the chest wall, which is not always possible in patients with trapped lung or extensive disease.
An alternative that has gained popularity is the indwelling pleural catheter. This is a thin, tunneled tube placed under the skin of the chest that connects to the pleural space. Patients or their caregivers can attach a drainage bottle at home and drain fluid as needed, typically every few days.9PubMed Central. Indwelling pleural catheters: complications and management strategies The catheter stays in for weeks to months and eliminates the need for repeated hospital visits. Research has shown that this approach provides effective respiratory relief and improved quality of life while being manageable entirely at home, with complications occurring rarely.10PubMed. Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter In a meaningful fraction of patients, the catheter’s presence eventually triggers the pleural surfaces to fuse on their own, achieving a spontaneous pleurodesis that allows the catheter to be removed.
For ascites, repeated paracentesis remains the mainstay, though some patients receive a peritoneal catheter for home drainage. Managing abdominal fluid is generally less amenable to permanent sealing procedures than pleural fluid, in part because the peritoneal surface is so large and the sources of fluid production so diffuse.
Targeted Therapies That Address the Root Cause
Because much of the fluid production in cancer is driven by VEGF-mediated vessel leakiness, drugs that block VEGF can sometimes reduce effusions at their source rather than simply draining the result. Bevacizumab, an antibody that neutralizes VEGF, has shown benefit specifically in ovarian cancer patients with ascites. In a large trial, women with ascites who received bevacizumab alongside chemotherapy had longer progression-free survival than those receiving chemotherapy alone, with a median improvement of roughly five months. Overall survival also improved modestly.11PubMed Central. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallotropic tube and peritoneal cancers: An NRG Oncology/GOG study The presence of ascites at baseline actually predicted who would benefit most from the drug, suggesting that the very patients with the worst fluid problems are the ones for whom anti-VEGF therapy makes the biggest difference.
A different approach has targeted the tumor cells floating in ascitic fluid directly. Catumaxomab, a bispecific antibody that grabs onto both tumor cells and immune cells, was approved in the European Union for treatment of malignant ascites from cancers that express a surface marker called EpCAM.12PubMed Central. Catumaxomab: clinical development and future directions Delivered directly into the abdominal cavity, it brings immune cells into close contact with tumor cells and destroys them, reducing the population of malignant cells that drives fluid production. Clinical trials showed that catumaxomab significantly extended the time patients could go between needing drainage procedures.13PubMed Central. Review of catumaxomab in the treatment of malignant ascites The drug’s commercial availability has been inconsistent over the years, but the principle it demonstrated, using immunotherapy to treat effusions at their biological source, has influenced ongoing research into next-generation antibodies and cellular therapies for malignant fluid collections.
Why the Same Cancer Can Cause Fluid in Different Places
A question patients often have is why cancer that started in one organ ends up causing fluid in a completely different part of the body. The answer has to do with how cancer spreads. When tumor cells break off from the primary site and travel through the bloodstream or lymphatic system, they tend to seed surfaces that are lined with thin membranes, such as the pleura, the peritoneum, and the pericardium. These membranes are rich in blood and lymphatic vessels, making them both a hospitable landing spot for tumor cells and a prime location for fluid production once the tumor disrupts local vessel integrity.
Ovarian cancer, for instance, is notorious for spreading across the peritoneal surface and causing massive ascites, but it can also produce pleural effusions, usually on the right side, even without obvious lung metastases. The explanation involves lymphatic channels that connect the abdominal and chest cavities through small defects in the diaphragm. Fluid and tumor cells migrate upward through these channels, seeding the pleural space from below. This is why treating the underlying cancer systemically, rather than just draining one cavity at a time, remains the most effective way to control fluid production across multiple sites.
Living with Recurrent Fluid Collections
For patients whose cancer cannot be cured, managing recurrent fluid buildup becomes a central part of daily life. The physical burden is real: large pleural effusions make climbing stairs feel like running a sprint, and tense ascites can make it impossible to eat a normal meal because the stomach has no room to expand. Sleep becomes difficult in any position. The repeated procedures, hospital visits, and disruptions to normal routines take a psychological toll as well.
Palliative care teams play a significant role for these patients, not just in managing symptoms but in planning the least disruptive drainage strategy. An indwelling catheter that allows home drainage may preserve more independence than twice-monthly trips to the hospital for needle drainage. Diuretics sometimes slow fluid reaccumulation modestly, though they tend to be less effective for malignant effusions than for fluid retention from heart failure or liver disease. Nutritional support to maintain albumin levels can help slow the cycle described earlier, though it rarely stops it entirely. The goal of management shifts from eliminating the fluid to giving patients as much functional time as possible between episodes of symptomatic accumulation.